DE69332779T2 - Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen - Google Patents

Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen

Info

Publication number
DE69332779T2
DE69332779T2 DE69332779T DE69332779T DE69332779T2 DE 69332779 T2 DE69332779 T2 DE 69332779T2 DE 69332779 T DE69332779 T DE 69332779T DE 69332779 T DE69332779 T DE 69332779T DE 69332779 T2 DE69332779 T2 DE 69332779T2
Authority
DE
Germany
Prior art keywords
serine
proteins
activine
applications
kinase domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69332779T
Other languages
English (en)
Other versions
DE69332779D1 (de
Inventor
Kohei Miyazono
Ten Dijke
Petra Franzen
Hidetoshi Yamashita
Carl-Henrik Heldin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research London
Original Assignee
Ludwig Institute for Cancer Research London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929224057A external-priority patent/GB9224057D0/en
Priority claimed from GB939304680A external-priority patent/GB9304680D0/en
Priority claimed from GB939304677A external-priority patent/GB9304677D0/en
Priority claimed from GB939311047A external-priority patent/GB9311047D0/en
Priority claimed from GB939313763A external-priority patent/GB9313763D0/en
Priority claimed from GB939316099A external-priority patent/GB9316099D0/en
Priority claimed from GB939321344A external-priority patent/GB9321344D0/en
Application filed by Ludwig Institute for Cancer Research London filed Critical Ludwig Institute for Cancer Research London
Publication of DE69332779D1 publication Critical patent/DE69332779D1/de
Application granted granted Critical
Publication of DE69332779T2 publication Critical patent/DE69332779T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
DE69332779T 1992-11-17 1993-11-17 Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen Expired - Lifetime DE69332779T2 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB929224057A GB9224057D0 (en) 1992-11-17 1992-11-17 Novel protein kinase receptors
GB939304680A GB9304680D0 (en) 1993-03-08 1993-03-08 Protein kinases
GB939304677A GB9304677D0 (en) 1993-03-08 1993-03-08 Protein kinases
GB939311047A GB9311047D0 (en) 1993-05-28 1993-05-28 Protein kinases
GB939313763A GB9313763D0 (en) 1993-07-02 1993-07-02 Protein kinases
GB939316099A GB9316099D0 (en) 1993-08-03 1993-08-03 Protein kinases
GB939321344A GB9321344D0 (en) 1993-10-15 1993-10-15 Protein kinases
PCT/GB1993/002367 WO1994011502A2 (en) 1992-11-17 1993-11-17 Activin receptor-like kinases, proteins having serine threonine kinase domains and their use

Publications (2)

Publication Number Publication Date
DE69332779D1 DE69332779D1 (de) 2003-04-24
DE69332779T2 true DE69332779T2 (de) 2003-10-23

Family

ID=27562887

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332779T Expired - Lifetime DE69332779T2 (de) 1992-11-17 1993-11-17 Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen

Country Status (10)

Country Link
US (5) US6316217B1 (de)
EP (1) EP0677104B1 (de)
JP (1) JP3362151B2 (de)
KR (1) KR950704485A (de)
AT (1) ATE234920T1 (de)
AU (1) AU683431B2 (de)
CA (1) CA2149441C (de)
DE (1) DE69332779T2 (de)
NZ (1) NZ257631A (de)
WO (1) WO1994011502A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592428B1 (en) * 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US6291206B1 (en) * 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US6248554B1 (en) * 1993-11-24 2001-06-19 The Procter & Gamble Company DNA sequence coding for a BMP receptor
US5863738A (en) * 1994-04-29 1999-01-26 Creative Biomolecules, Inc. Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
US6210899B1 (en) 1994-11-04 2001-04-03 The Procter & Gamble Company Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor
US6306622B1 (en) 1994-11-04 2001-10-23 The Procter & Gamble Co. cDNA encoding a BMP type II receptor
EP0845006A2 (de) * 1995-08-14 1998-06-03 Creative Biomolecules, Inc. Bindung des osteogenen proteins-i (op-1) und dessen analoge an den zelloberflächenrezeptor alk-1 und dessen analoge
AU6421498A (en) * 1997-04-28 1998-11-24 Helix Research Institute Serine/threonine protein kinase
AU3092899A (en) * 1998-03-13 1999-09-27 Ludwig Institute For Cancer Research Alk-1 responds to tgf-beta and signals through smad-1 and smad-5
WO2002094084A2 (en) * 2001-05-21 2002-11-28 University Of Iowa Research Foundation Bmpr1a involvement in juvenile polyposis
DE602004022315D1 (de) * 2003-09-15 2009-09-10 Res Dev Foundation Cripto-antagonismus von activin und tgf-b signalisierung
WO2005077403A1 (en) * 2004-02-04 2005-08-25 Stryker Corporation Therapeutic methods using smads
AU2005265098B2 (en) 2004-06-17 2012-02-23 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
CA2621371C (en) 2005-09-07 2018-05-15 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
EP1945258A4 (de) 2005-09-20 2011-08-17 Thrasos Therapeutics Inc Mit tdf verwandte verbindungen und analoga davon
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
MX2009004718A (es) 2006-11-02 2009-06-19 Acceleron Pharma Inc Antagonistas de receptor de alk1 y ligando y sus usos.
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
WO2009134428A2 (en) 2008-05-02 2009-11-05 Acceleron Pharma, Inc. Methods and compositions for modulating angiogenesis and pericyte composition
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
ES2575695T3 (es) 2009-03-30 2016-06-30 Acceleron Pharma Inc. Antagonistas de BMP-ALK3 y sus usos para estimular el crecimiento óseo
EP2844246A4 (de) * 2012-05-04 2016-02-24 Univ Oklahoma Substrate und hemmer der prolyloligopeptidase und fibroblastenaktivierungsprotein sowie verfahren zur verwendung
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CN114736307A (zh) 2015-04-06 2022-07-12 阿塞勒隆制药公司 TGF-β超家族I型和II型受体异多聚体及其用途
CN105738630A (zh) * 2016-02-16 2016-07-06 林兴 丝/苏氨酸激酶抑制蛋白在治疗免疫性肝纤维化药物中的应用
CN105617369A (zh) * 2016-02-17 2016-06-01 林兴 丝/苏氨酸激酶抑制蛋白在治疗化学性肝纤维化药物中的应用
ES2875905T3 (es) 2016-07-15 2021-11-11 Acceleron Pharma Inc Composiciones que comprenden polipéptidos ActRIIA para su uso en el tratamiento de la hipertensión pulmonar
WO2018014829A1 (en) 2016-07-20 2018-01-25 Novartis Ag Aminopyridine derivatives and their use as selective alk-2 inhibitors
CN110678195A (zh) 2016-10-05 2020-01-10 阿塞勒隆制药公司 ALK4:ActRIIB异多聚体及其用途
CU20200035A7 (es) 2017-11-24 2021-03-11 Novartis Ag Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2
WO2022046840A1 (en) * 2020-08-26 2022-03-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Hybrid allosteric receptor-engineered stem cells
WO2023019185A1 (en) * 2021-08-10 2023-02-16 Gentibio, Inc. Compositions and methods for engineering stable tregs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154434B1 (de) * 1984-02-17 1993-01-27 Genentech, Inc. Menschlicher Transformationswachstumsfaktor und Vorläufer oder Fragment hiervon, Zellen, DNA, Vektoren und Verfahren zu ihrer Herstellung, Zusammensetzungen und Produkte, die diese enthalten, sowie davon abgeleitete Antikörper und Diagnostizierverfahren
WO1993019177A1 (en) * 1992-03-18 1993-09-30 The General Hospital Corporation FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY
WO1994029458A1 (en) * 1993-06-07 1994-12-22 Amgen Inc. Hybrid receptor molecules
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US6248554B1 (en) 1993-11-24 2001-06-19 The Procter & Gamble Company DNA sequence coding for a BMP receptor
US5863738A (en) * 1994-04-29 1999-01-26 Creative Biomolecules, Inc. Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor

Also Published As

Publication number Publication date
US6271365B1 (en) 2001-08-07
WO1994011502A3 (en) 1994-07-07
US6331621B1 (en) 2001-12-18
US20020123139A1 (en) 2002-09-05
JPH08505049A (ja) 1996-06-04
AU5432094A (en) 1994-06-08
AU683431B2 (en) 1997-11-13
CA2149441C (en) 2004-03-02
EP0677104A1 (de) 1995-10-18
ATE234920T1 (de) 2003-04-15
KR950704485A (ko) 1995-11-20
WO1994011502A2 (en) 1994-05-26
US6207814B1 (en) 2001-03-27
US6316217B1 (en) 2001-11-13
US6982319B2 (en) 2006-01-03
EP0677104B1 (de) 2003-03-19
NZ257631A (en) 1996-03-26
JP3362151B2 (ja) 2003-01-07
DE69332779D1 (de) 2003-04-24
CA2149441A1 (en) 1994-05-26

Similar Documents

Publication Publication Date Title
DE69332779T2 (de) Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen
CO4180381A1 (es) Derivados opticamente activos de 2-imidazolin-5-onas y 2- imidazolina-5-tionas fungicidas
AU5580496A (en) Domains of extracellular region of human platelet derived growth factor receptor polypeptides
TR200101858T2 (tr) JNK protein kinaz inhibitörleri olarak 4-ariloksindoller
ES2173864T3 (es) Compuestos heteroarilicos sustituidos con estirilo que inhiben tirosina quinasa del receptor de egf.
NO952398D0 (no) Pyrrolpyrimidiner som CRF antagonister
PT711292E (pt) Compostos espiro aza actuando no sistema colinergico com actividade agonista muscarinica
AR007857A1 (es) Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
DE69608916T2 (de) Verbindungen und ihre zusammensetzungen mit entzündungshemmenden und anti-thrombotischen wirkungen
DE69533484D1 (de) Verwendung von disubstituierten acetylenen mit heteroaromatischen und heterobicyclischen gruppen mit retinoidähnlicher aktivität
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
CO5190686A1 (es) Compuesto de indazol y composiciones farmaceuticas para la inhibicion de proteina kinasa
ES2138977T3 (es) Agonistas muscarinicos.
BR9711805A (pt) Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
WO2000035906A3 (en) 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
ES2172083T3 (es) Composicion limpiadora antibacteriana ultrasuave para uso frecuente.
ATE469981T1 (de) Tests auf proteinkinasen mit fluoreszierenden proteinsubstraten
DE69221232T2 (de) Silikongelzusammensetzung mit ausgezeichneter Dämpfungseigenschaft
BR0003474A (pt) Artigo absorvente compreendendo fibras floculadas
DE68918217D1 (de) Familie von modifizierten Antikörpern mit hoher Affinität zur Behandlung von Krebs.
PE26499A1 (es) Capa de adquisicion de liquido para articulos absorbentes
BR9607335A (pt) Compostos 1-aril-2-acrilamino-etano e seu uso como neuroquinina especialmente antogonistas de neuroquinina 1
PT1086096E (pt) Benzamidas com substituintes etra-hidrofuraniloxi como inibidores da fosfodiesterase 4
YU78092A (sh) Postupak za dobijanje derivata beta-fenilizoserina i njihova primena
TR200101745T2 (tr) 4,5-Azolo-oksindoller

Legal Events

Date Code Title Description
8364 No opposition during term of opposition